CELC
Celcuity Inc.
Company Overview
| Mkt Cap | $4.24B | Price | $99.43 |
| Volume | 868.47K | Change | +5.77% |
| P/E Ratio | -37.9 | Open | $92.89 |
| Revenue | -- | Prev Close | $94.00 |
| Net Income | $-111.8M | 52W Range | $7.58 - $94.06 |
| Div Yield | N/A | Target | $89.88 |
| Overall | 57 | Value | 40 |
| Quality | -- | Technical | 75 |
No chart data available
About Celcuity Inc.
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). It also engages in developing CELsignia diagnostic platform. The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is based in Minneapolis, Minnesota.
Latest News
Celcuity Submits NDA for Gedatolisib to FDA
Analysts Offer Insights on Healthcare Companies: Celcuity (CELC) and Pelthos Therapeutics (PTHS)
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), NeurAxis, Inc. (NRXS) and Celcuity (CELC)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CELC | $99.43 | +5.8% | 868.47K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |